Cytokine-induced memory-like (CIML) natural killer (NK) cells from a haploidentical (half-matched) donor, to treat acute myeloid leukemia (AML) that has come back (relapsed) or has not gotten better with treatment (refractory)


18 and older

Phase 1, Phase 2

1 Location


Clinical Trial Goal

To find out if CIML-NK cells are safe and work well to treat AML that has relapsed or is refractory

You may be able to join this trial if you:

  • Are 18 years or older
  • Have AML that has relapsed or is refractory
  • Have a half-matched related donor. Your biological parents and children may be a half match for you
  • Agree to have other standard tests done to see if you can be in the clinical trial 

Trial Details

CIML-NK cells are a type of allogeneic (cells from a donor) immune cell that doctors think will attack and kill cancer cells. 

You’ll get:
  • CIML-NK cells – Given as an intravenous (IV) infusion. The dose you'll get depends on when you start the trial and how safe it has been

You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 6 months.

The Food and Drug Administration (FDA) has not yet approved CIML-NK cells


Evelyn Nguyen, 513-636-4379,

Michele Wang, 513-517-7219,


Cincinnati Children's Hospital Medical CenterRecruiting

Cincinnati, Ohio
Contacts: record

NCT05580601. First posted on 10/14/22

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator